[Squamous cell carcinoma of the hypopharynx and larynx: evidence-based care]

Bull Cancer. 2014 May 1;101(5):438-44. doi: 10.1684/bdc.2014.1945.
[Article in French]

Abstract

Squamous cell carcinomas of larynx and hypopharynx can be treated by surgery and/or radiotherapy according to tumor size. For small tumors, the results are similar. For locally advanced tumors, the surgical approach is mutilating and requires a total (pharyngo)laryngectomy. Exclusive chemoradiotherapy has shown its interest at the cost of late sequelae. In order to reduce these effects and mutilation, induction chemotherapy with cisplatin, docetaxel and 5FU for organ preservation becomes the standard treatment but there are no solid studies comparing this approach with the exclusive chemoradiotherapy. And it is not possible to conclude as to the superiority of a scheme in terms of overall survival. When chemotherapy is chosen, the modalities of any potentiation of radiation have not been yet established.

Keywords: TPF; chemoradiotherapy; hypopharynx; induction; larynx.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy*
  • Chemoradiotherapy / methods
  • Evidence-Based Medicine
  • Humans
  • Hypopharyngeal Neoplasms / pathology
  • Hypopharyngeal Neoplasms / therapy*
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / therapy*
  • Lymphatic Metastasis
  • Neoplasm Staging / methods
  • Tumor Burden

Substances

  • Antineoplastic Agents